The DOI matches its Crossref record; 297 of the 297 references it cites were found in a registry or an index.
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Open accessAbstract
The immune system and cancer have a complex relationship with the immune system playing a dual role in tumor development. The effector cells of the immune system can recognize and kill malignant cells while immune system-mediated inflammation can also promote tumor growth and regulatory cells suppress the anti-tumor responses. In the center of all anti-tumor responses is the ability of the immune cells to migrate to the tumor site and to interact with each other and with the malignant cells. Cell adhesion molecules including receptors of the immunoglobulin superfamily and integrins are of crucial importance in mediating these processes. Particularly integrins play a vital role in regulating all aspects of immune cell function including immune cell trafficking into tissues, effector cell activation and proliferation and the formation of the immunological synapse between immune cells or between immune cell and the target cell both during homeostasis and during inflammation and cancer. In this review we discuss the molecular mechanisms regulating integrin function and the role of integrins and other cell adhesion molecules in immune responses and in the tumor microenvironment. We also describe how malignant cells can utilize cell adhesion molecules to promote tumor growth and metastases and how these molecules could be targeted in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–297 of 297
Jalkanen, S., Karikoski, M., Mercier, N., Koskinen, K., Henttinen, T. A., Elima, K., Salmivirta, K., & Salmi, M. (2007) · Blood · doi:10.1182/blood-2007-01-069674 · Cited by 108
Structural mechanism of integrin inactivation by filamin
Liu, J., Das, M., Yang, J., Ithychanda, S. S., Yakubenko, V. P., Plow, E. F., & Qin, J. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2999 · Cited by 108
Kindlin-2 directly binds actin and regulates integrin outside-in signaling
Bledzka, K., Bialkowska, K., Sossey-Alaoui, K., Vaynberg, J., Pluskota, E., Qin, J., & Plow, E. F. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201501006 · Cited by 107
Usami, Y., Ishida, K., Sato, S., Kishino, M., Kiryu, M., Ogawa, Y., Okura, M., Fukuda, Y., & Toyosawa, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28066 · Cited by 105
Anderson, K. E., Boyle, K. B., Davidson, K., Chessa, T. A. M., Kulkarni, S., Jarvis, G. E., Sindrilaru, A., Scharffetter‐Kochanek, K., Rausch, O., Stephens, L., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149450 · Cited by 104
Manevich, E., Feigelson, S. W., Pasvolsky, R., Aker, M., Grabovsky, V., Shulman, Z., Kılıç, S. Ş., Rosenthal‐Allieri, M. A., Ben‐Dor, S., Mory, A., et al. (2009) · Blood · doi:10.1182/blood-2009-04-218636 · Cited by 104
The role of ICAM-1 molecule in the migration of Langerhans cells in the skin and regional lymph node
Xu, H., Guan, H., Zu, G., Bullard, D. C., Hanson, J., Slater, M., & Elmets, C. A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3085::aid-immu3085>3.0.co;2-b · Cited by 103
Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer
Schröder, C., Witzel, I., Müller, V., Krenkel, S., Wirtz, R. M., Jänicke, F., Schumacher, U., & Milde‐Langosch, K. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-0984-2 · Cited by 103
dos Santos, P. B., Zanetti, J. S., Ribeiro‐Silva, A., & Beltrão, E. I. U. F. D. P. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-104 · Cited by 102
Delbaldo, C., Raymond, É., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M. E., & Faivre, S. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9077-0 · Cited by 101
Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats
Palmen, M. J. H. J., Dijkstra, C. D., van der Ende, M. B., Peña, A. S., & van Rees, E. P. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb08363.x · Cited by 99
Vermorken, J. B., Peyrade, F., Krauss, J. C., Mesı́a, R., Remenár, É., Gauler, T. C., Keilholz, U., Delord, J., Schafhausen, P., Erfan, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu003 · Cited by 98
CD18 Is Required for Optimal Development and Function of CD4+CD25+ T Regulatory Cells
Marski, M., Kandula, S., Turner, J. R., & Abraham, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7889 · Cited by 97
Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™
Mulgrew, K. A., Kinneer, K., Yao, X.-T., Ward, B. K., Damschroder, M. M., Walsh, B., Mao, S.-Y., Gao, C., Kiener, P. A., Coats, S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0356 · Cited by 96
Ma, J., Wang, J.-H., Guo, Y., Sy, M., & Bigby, M. E. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1285 · Cited by 92
LFA-1 on CD4+ T Cells Is Required for Optimal Antigen-Dependent Activation In Vivo
Kandula, S., & Abraham, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4443 · Cited by 91
Efalizumab: a review of events reported during clinical trials and side effects
Scheinfeld, N. S. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.2.197 · Cited by 91
Ahsmann, E., Lokhorst, H. M., Dekker, A. W., & Bloem, A. C. (1992) · Blood · doi:10.1182/blood.v79.8.2068.2068 · Cited by 91
Genetic etiologies of leukocyte adhesion defects
Etzioni, A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.07.005 · Cited by 90
β2 integrins are required for skin homing of primed T cells but not for priming naive T cells
Grabbe, S., Varga, G., Beissert, S., Steinert, M., Pendl, G. G., Seeliger, S., Bloch, W., Peters, T., Schwarz, T., Sunderkötter, C. H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci11703 · Cited by 90
Besse, B., Tsao, L. C., Chao, D. T., Fang, Y., Soria, J., Almokadem, S., & Belani, C. P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds281 · Cited by 89
Foubert, P., Kaneda, M. M., & Varner, J. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0143 · Cited by 89
Klapproth, S., Sperandio, M., Pinheiro, E. M., Pruenster, M., Soehnlein, O., Gertler, F. B., Fässler, R., & Moser, M. (2015) · Blood · doi:10.1182/blood-2015-05-647453 · Cited by 88
Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer
Maeda, K., Kang, S., Sawada, T., Nishiguchi, Y., Yashiro, M., Ogawa, Y., Ohira, M., Ishikawa, T., & Chung, K. H.-Y. (2002) · Oncology Reports · doi:10.3892/or.9.3.511 · Cited by 88
Rose, D. M., Liu, S., Woodside, D. G., Han, J., Schlaepfer, D. D., & Ginsberg, M. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5912 · Cited by 87
Bhaskar, V., Zhang, D., Fox, M., Seto, P., Wong, M. H. L., Wales, P., Powers, D., Chao, D. T., DuBridge, R. B., & Ramakrishnan, V. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-61 · Cited by 87
Biology and structure of leukocyte β2 integrins and their role in inflammation
Arnaout, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9415.1 · Cited by 87
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
Kim, K. B., Prieto, V. G., Joseph, R. W., Diwan, A. H., Gallick, G. E., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Hwu, P., Ng, C. S., et al. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835312e4 · Cited by 83
Wu, T.-C., Xu, K., Banchereau, R., Marches, F., Yu, C. I., Martínek, J., Anguiano, E., Pedroza‐González, A., Snipes, G. J., O’Shaughnessy, J., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0217 · Cited by 82
Tumor angiogenesis factors reduce leukocyte adhesion in vivo
Tromp, S. C., Egbrink, M. G. A. O., Dings, R. P. M., van Velzen, S., Slaaf, D. W., Hillen, H. F. P., Tangelder, G. J., Reneman, R. S., & Griffioen, A. W. (2000) · International Immunology · doi:10.1093/intimm/12.5.671 · Cited by 81
Rap1 and its effector RIAM are required for lymphocyte trafficking
Su, W., Wynne, J. P., Pinheiro, E. M., Strazza, M., Mor, A., Montenont, E., Berger, J. S., Paul, D. S., Bergmeier, W., Gertler, F. B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644104 · Cited by 80
Rossi, D., Zucchetto, A., Rossi, F. M., Capello, D., Cerri, M., Deambrogi, C., Cresta, S., Rasi, S., Paoli, L. D., Bodoni, C. L., et al. (2008) · Haematologica · doi:10.3324/haematol.13103 · Cited by 80
Koyama, S., Ebihara, T., & Fukao, K. (1992) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01211806 · Cited by 79
Heidenreich, A., Rawal, S. K., Szkarlat, K., Bogdanova, N. V., Dirix, L. Y., Stenzl, A., Welslau, M., Wang, G., Dawkins, F. W., de Boer, C. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds505 · Cited by 79
Hussain, M., Moulec, S. L., Gimmi, C. D., Bruns, R., Straub, J., & Miller, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2512 · Cited by 77
Vansteenkiste, J., Barlési, F., Waller, C. F., Bennouna, J., Gridelli, C., Goekkurt, E., Verhoeven, D., Szczęsna, A., Feurer, M., Milanowski, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv219 · Cited by 76
Abraham, C., Griffith, J., & Miller, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4399 · Cited by 75
Hartmann, T. N., Grabovsky, V., Wang, W., Desch, P., Rubenzer, G., Wollner, S., Binsky, I., Vallon-Eberhard, A., Sapoznikov, A., Burger, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4136 · Cited by 75
Huet-Calderwood, C., Brahme, N. N., Kumar, N., Stiegler, A. L., Raghavan, S., Boggon, T. J., & Calderwood, D. (2014) · Journal of Cell Science · doi:10.1242/jcs.155879 · Cited by 75
T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma
Weishaupt, C., Munoz, K. N., Buzney, E. A., Kupper, T. S., & Fuhlbrigge, R. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2450 · Cited by 74
Functional redundancy between RAP1 isoforms in murine platelet production and function
Stefanini, L., Lee, R. H., Paul, D. S., O’Shaughnessy, E. C., Ghalloussi, D., Jones, C. I., Boulaftali, Y., Poe, K. O., Piatt, R., Kechele, D. O., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838714 · Cited by 73
The Integrin LFA-1 Controls T Follicular Helper Cell Generation and Maintenance
Meli, A. P., Fontès, G., Avery, D. T., Leddon, S. A., Tam, M., Elliot, M., Ballesteros‐Tato, A., Miller, J., Stevenson, M. M., Fowell, D. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.018 · Cited by 72
Mita, M., Kelly, K. R., Mita, A., Ricart, A. D., Romero, O., Tolcher, A., Hook, L., Okereke, C., Krivelevich, I., Rossignol, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0010 · Cited by 71
Morrison, V. L., MacPherson, M., Savinko, T., Lek, H. S., Prescott, A. R., & Fagerholm, S. C. (2013) · Blood · doi:10.1182/blood-2013-02-484998 · Cited by 70
Self-citationRiches, J. C., O’Donovan, C. J., Kingdon, S. J., McClanahan, F., Clear, A. J., Neuberg, D. S., Werner, L. L., Croce, C. M., Ramsay, A. G., Rassenti, L. Z., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552307 · Cited by 70
Morrison, V. L., James, M., Grzes, K. M., Cook, P. C., Glass, D. G., Savinko, T., Lek, H. S., Gawden‐Bone, C. M., Watts, C. K. W., Millington, O. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms6359 · Cited by 68
Self-citationContact-Dependent T Cell Activation and T Cell Stopping Require Talin1
Wernimont, S. A., Wiemer, A. J., Bennin, D. A., Monkley, S. J., Ludwig, T. E., Critchley, D. R., & Huttenlocher, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102028 · Cited by 68
Wang, H., Peters, T., Sindrilaru, A., Keß, D., Oreshkova, T., Yu, X., Seier, A. M., Schreiber, H. A., Wlaschek, M., Blakytny, R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34916 · Cited by 67
Kindlin supports platelet integrin αIIbβ3 activation by interacting with paxillin
Gao, J., Huang, M., Lai, J., Mao, K., Sun, P., Cao, Z., Hu, Y., Zhang, Y., Schulte, M. L., Jin, C., et al. (2017) · Journal of Cell Science · doi:10.1242/jcs.205641 · Cited by 65
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Gerstner, E. R., Ye, X., Duda, D. G., Levine, M. A., Mikkelsen, T., Kaley, T. J., Olson, J. J., Nabors, B., Ahluwalia, M. S., Wen, P. Y., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov085 · Cited by 64
Afanasiev, O. K., Nagase, K., Simonson, W., Vandeven, N. A., Blom, A., Koelle, D. M., Clark, R. A., & Nghiem, P. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.36 · Cited by 64
Cirkel, G. A., Kerklaan, B. M., Vanhoutte, F. P., der Aa, A. V., Lorenzon, G., Namour, F., Pujuguet, P., Darquenne, S., Vos, F. D., Snijders, T. J., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-015-0320-9 · Cited by 64
Fu, X., Rivera, A. M., Tao, L., & Zhang, X. (2013) · International Journal of Cancer · doi:10.1002/ijc.28269 · Cited by 63
CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment
Zhang, Q., Hu, X., Liu, Y.-L., Ye, Z.-J., Gui, Y.-H., Zhou, D., Qi, C., He, X., Wang, H., & Wang, L. (2015) · Scientific Reports · doi:10.1038/srep15948 · Cited by 63
Bradley, D., Daignault, S. D., Ryan, C. J., DiPaola, R. S., Smith, D. C., Small, E. J., Gross, M. E., Stein, M. N., Chen, A. P., & Hussain, M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9420-8 · Cited by 61
Balkow, S., Heinz, S., Schmidbauer, P., Kolanus, W., Holzmann, B., Grabbe, S., & Laschinger, M. (2010) · Blood · doi:10.1182/blood-2009-05-224428 · Cited by 60
Bao, W., & Strömblad, S. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404018 · Cited by 59
Capece, T., Walling, B. L., Lim, K., Kim, K., Bae, S., Chung, H.-L., Topham, D. J., & Kim, M. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201609072 · Cited by 56
Yanguas, A., Garasa, S., Teijeira, Á., Aubá, C., Melero, I., & Rouzaut, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02084 · Cited by 56
Integrin αvβ3 Controls Activity and Oncogenic Potential of Primed c-Src
Huveneers, S., van den Bout, I., Sonneveld, P., Sancho, A., Sonnenberg, A., & Danen, E. H. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3654 · Cited by 55
LFA-1 is critical for regulatory T cell homeostasis and function
Wohler, J. E., Bullard, D. C., Schoeb, T. R., & Barnum, S. R. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.004 · Cited by 55
Khasraw, M., Lee, A., McCowatt, S., Kerestes, Z., Buyse, M. E., Back, M., Kichenadasse, G., Ackland, S. P., & Wheeler, H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2094-0 · Cited by 54
Improving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 54
LFA-1 Affinity Regulation Is Necessary for the Activation and Proliferation of Naive T Cells
Wang, Y., Li, D., Nurieva, R., Yang, J. S., Şen, M., Carreño, R., Lu, S., McIntyre, B. W., Molldrem, J. J., Legge, G. B., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807207200 · Cited by 52
Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders.
Lúcio, P., Faria, M. T., Pinto, A., da Silva, M. G., Júnior, M. E. C., Costa, R., & Parreira, A. (1998) · PubMed · Cited by 52
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
Haddad, T. C., Qin, R., Lupu, R., Satele, D., Eadens, M., Goetz, M. P., Erlichman, C., & Molina, J. R. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3322-9 · Cited by 52
Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva
Seminara, N. M., & Gelfand, J. M. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.01.001 · Cited by 51
Tachimori, A., Yamada, N., Sakate, Y., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.036 · Cited by 49
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses
Kwan, B. H., Zhu, E. F., Tzeng, A., Sugito, H. R., Eltahir, A., Ma, B., Delaney, M. K., Murphy, P. A., Kauke, M. J., Angelini, A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160831 · Cited by 49
Savinko, T., Guenther, C., Uotila, L. M., Asens, M. L., Yao, S., Tojkander, S., & Fagerholm, S. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700913 · Cited by 49
Self-citationSelectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils
Yago, T., Zhang, N., Zhao, L., Abrams, C. S., & McEver, R. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015602 · Cited by 49
Talamonti, M., Spallone, G., Stefani, A. D., Costanzo, A., & Chimenti, S. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.524925 · Cited by 47
Wirth, M., Heidenreich, A., Gschwend, J. E., Gil, T., Zastrow, S., Laniado, M., Gerloff, J., Zühlsdorf, M., Mordenti, G., Uhl, W., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.051 · Cited by 43
Molecular Mechanisms of IL-2 Gene Regulation Following Costimulation Through LFA-1
Abraham, C., & Miller, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5193 · Cited by 41
LFA-1 integrin antibodies inhibit leukocyte α4β1–mediated adhesion by intracellular signaling
Grönholm, M., Jahan, F., Bryushkova, E. A., Madhavan, S., Aglialoro, F., Hinojosa, L. S., Uotila, L. M., & Gahmberg, C. G. (2016) · Blood · doi:10.1182/blood-2016-03-705160 · Cited by 37
Blank, C. A., Brown, I. E., Kacha, A. K., Markiewicz, M. A., & Gajewski, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3416 · Cited by 34
A phase I study of continuous infusion cilengitide in patients with solid tumors
O’Donnell, P. H., Undevia, S. D., Stadler, W. M., Karrison, T. M., Nicholas, M. K., Janisch, L. A., & Ratain, M. J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9537-9 · Cited by 33
Mukai, S., Kagamu, H., Shu, S., & Plautz, G. E. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1439 · Cited by 33
Kerklaan, B. M., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., Vos, F. D., Dean, E. J., Reyderman, L., Ottesen, L. H., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0344-9 · Cited by 32
Cell Motility in Chronic Lymphocytic Leukemia: Defective Rap1 and αLβ2 Activation by Chemokine
Till, K. J., Harris, R. J., Linford, A., Spiller, D. G., Zuzel, M., & Cawley, J. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1758 · Cited by 31
Figlin, R. A., Kondagunta, G. V., Yazji, S., Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4535 · Cited by 31
Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa
Enarsson, K., Johnsson, E., Lindholm, C., Lundgren, A., Pan‐Hammarström, Q., Strömberg, E., Bergin, P. J., Baunge, E.-L., Svennerholm, A., & Quiding‐Järbrink, M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.08.001 · Cited by 28
Li, M., Lin, J., Wang, Z., He, S., Ma, X., & Li, D. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000315084 · Cited by 27
Evans, T., Ramanathan, R. K., Yazji, S., Glynne‐Jones, R., Anthoney, A., Berlin, J. D., & Valle, J. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4549 · Cited by 27
Activating Ly-49 Receptors Regulate LFA-1-Mediated Adhesion by NK Cells
Osman, M. S., Burshtyn, D. N., & Kane, K. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1261 · Cited by 23
Fine-tuning Tumor Immunity with Integrin Trans-regulation
Cantor, J. M., Rose, D. M., Slepak, M., & Ginsberg, M. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0226 · Cited by 23
Morrison, V. L., Uotila, L. M., Asens, M. L., Savinko, T., & Fagerholm, S. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402741 · Cited by 22
Self-citationSelective in vivo growth of lymphocyte function- associated antigen-1–positive murine myeloma cells
Asosingh, K., Vankerkhove, V., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)00970-0 · Cited by 21
Hotblack, A., Holler, A., Piapi, A., Ward, S., Stauss, H. J., & Bennett, C. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.011 · Cited by 21
Functional Beta2-Integrins Restrict Skin Inflammation In Vivo
Savinko, T., Morrison, V. L., Uotila, L. M., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.164 · Cited by 20
Haasken, S., Auger, J. L., & Binstadt, B. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000967 · Cited by 20
Nowatzky, J., Manches, O., Khan, S. A., Godefroy, E., & Bhardwaj, N. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.005 · Cited by 20
A phase I dose-escalation study of IMGN388 in patients with solid tumors.
Thompson, D. S., Patnaik, A., Bendell, J. C., Papadopoulos, K., Infante, J. R., Mastico, R. A., Johnson, D. H., Qin, A., O'Leary, J. J., & Tolcher, A. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3058 · Cited by 16
The angiogenic factor bFGF impairs leukocyte adhesion and rolling under flow conditions
Griffioen, A. W., Relou, I. A. M., Torres, H. I. G., Damen, C. A., Martinotti, S., de Graaf, J. C., Zwaginga, J. J., & Groenewegen, G. (1998) · Angiogenesis · doi:10.1023/a:1009237324501 · Cited by 14
Nakahara, T., Oba, J., Shimomura, C., Kido‐Nakahara, M., & Furue, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.359 · Cited by 13
Dold, S., Laschke, M. W., Lavasani, S., Menger, M. D., & Thorlacius, H. (2008) · Surgery · doi:10.1016/j.surg.2008.05.010 · Cited by 13
Uronis, H. E., Jia, J., Bendell, J. C., Howard, L. A., Ready, N., Lee, P. H., Starr, M. D., Dellinger, A. E., Pang, H., Nixon, A. B., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2647-x · Cited by 12
Cited by
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Bui, T. M., Wiesolek, H. L., & Sumagin, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mr0220-549r · Cited by 957
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Cell adhesion in cancer: Beyond the migration of single cells
Janiszewska, M., Primi, M. C., & Izard, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.007759 · Cited by 646
Metadata
- Authors
- Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-05-22
- Volume
- 10
- Pages
- 1078-1078
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2945537500
- Cited by
- 764
- References
- 297
- FWCI
- 49.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.